Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM).

Xue Bai,Alexander N. Shoushtari,Allison Betof Warner,Henry Quach,Christopher G. Cann,Michael Zhang,Lalit Pallan,Catriona Harvey,Lu Si,Bixia Tang,Chuanliang Cui,Michelle S Kim,Tatyana Sharova,Keith T. Flaherty,Georgina V. Long,Alexander M. Menzies,Ryan J. Sullivan,Genevieve M. Boland,Douglas B. Johnson,Jun Guo

Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM).

2021

9530Background: Ultraviolet (UV)-induced high tumor mutation burden (TMB) of NACM is associated with response to anti-PD-1 monotherapy (aPD-1). Anatomic location of the primary lesion (reflecting U...

Keywords:

Immune system
in patient
Oncology
Internal medicine
Medicine
Adverse effect
Primary sites
cutaneous melanoma
anti pd 1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations